期刊文献+

慢性肾疾病继发性甲状旁腺功能亢进的治疗现状及研究 被引量:4

The Rapeutic Status and Study Progress of Secondary Hyperparathyroidism of Chronic Kidney Disease
下载PDF
导出
摘要 继发性甲状旁腺功能亢进是慢性肾脏疾病中最常见的并发症之一,临床上常表现为各种骨病和钙磷代谢紊乱,如骨质疏松、骨折、顽固性皮肤搔痒、心血管钙化等等,严重影响患者的生存质量。现就目前临床上在治疗中存在的问题和近期的研究新进展进行讨论。 Secondary Hyperparathyroidism is one of the most common clinical complications of Chronic Kidney Disease(CKD). Its clinical manifestation includes all kinds of bone diseases and disorders of phosphorus metabolism, such as osteoporosis, bone fracture, refractoriy skin itch, angiosteosis and so on, which will affect the quality of life of patients with this disease seriously. This article reviews problems suspending in current clinical therapies and progresses about related study.
作者 顾波 路建饶
出处 《医学综述》 2008年第12期1826-1828,共3页 Medical Recapitulate
关键词 慢性肾疾病 继发性甲状旁腺功能亢进 治疗 Chronic kidney disease Secondary hyperparathyroidism Therapy
  • 相关文献

参考文献18

  • 1Slatopolsky E, Dusso A, Brown AJ. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure [ J ]. Am J Med Sci, 1999,317 (6) :370-376. 被引量:1
  • 2Chertow G, Burke S, Dillon M,et al. Long term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients [ J ]. Nephrol Dial Transplant, 1999, 14 (12) :2907-2914. 被引量:1
  • 3Albaaj F, Hutchison AJ. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients [ J ]. Expert Opin Pharmacother,2005,6(2) :319-328. 被引量:1
  • 4Mucsi I, Hercz G, Uldall R ,et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis [ J ]. Kidney Int, 1998,53 (5) : 1399-1404. 被引量:1
  • 5Lugon JR, Andre ME, Duarte ME, et al. Effects of in center daily hemodialysis upon mineral metabolism and bone disease in end stage renal disease patients[ J]. Sao Paulo Med J,2001,119 (3) : 105-109. 被引量:1
  • 6Boran M, Doruk E, Gonenc F, et al. 1,25 ( OH ) 2 cholecalciferol pulse therapy and the effects of different dialysis membranes on serum PTH levels of hemodialysis patients [ J ]. Int Urol Nephrol, 1997,29(2) :251-258. 被引量:1
  • 7Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end - stage renal disease [ J ]. Am J Nephrol, 1996,16 (5) :386-393. 被引量:1
  • 8Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism [ J]. Kidney Int,2000,58 ( 1 ) :436-445. 被引量:1
  • 9Goodman WG. Renal osteodystrophy : present and future [ J ]. Clin Exp Nehrol, 2000,4 ( 6 ) : 182-188. 被引量:1
  • 10Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure[J]. Kidney Int,1998,53( 1 ) :223-227. 被引量:1

同被引文献44

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部